A Certified Reference Material
Features
  • This product is qualified as a Certified Reference Material (CRM) that has been manufactured and tested to meet ISO/IEC 17025 and ISO 17034 international standards
  • This CRM has been characterized by metrologically valid procedures and may be used as a quantitative analytical reference standard
  • Certificate of analysis provides the certified property values and the associated uncertainties, including a statement of metrological traceability for the certified values
  • Possession of a DEA Controlled Substance registration is not necessary nor is a DEA 222 form required to purchase this product
  • Bulk material is available for qualified institutions; please contact our sales department for pricing
Related Products
Alternative(s)
40658Lorazepam-d4 18728Lorazepam-d4 (CRM)
Reference Material(s)
17965Lorazepam-13C2-d4
Unlabeled Version(s)
15891Lorazepam ISO60202Lorazepam (CRM)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Lorazepam-13C2-d4 (CRM)

A 100 µg/ml solution in acetonitrile

Item No. 18731

Exempt Product (US)
Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
7-chloro-5-(2-chlorophenyl-d4)-3-hydroxy-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one-2,3-13C2
CAS Number
2747915-04-2
Molecular Formula
C13[13C]2H6D4Cl2N2O2
Formula Weight
327.2
Formulation
A 100 µg/ml solution in acetonitrile
SMILES
ClC1=C([2H])C([2H])=C([2H])C([2H])=C1C(C(C=C(Cl)C=C2)=C2N3)=N[13CH](O)[13C]3=O
InChi Code
InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)/i1D,2D,3D,4D,14+1,15+1
InChi Key
DIWRORZWFLOCLC-FCIHXEGWSA-N
Regulatory Information
DEA Exempt Notification
This product is a DEA exempt preparation of a scheduled compound - does not require DEA Controlled Substance registration or DEA 222 form. For alternate sizes please contact sales.
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 µg

    $132

    Add
    Cayman Chemical
    Forensic Lab Guide Wall Posters

    Discover our collection of drug identification, naming, and metabolism posters for your lab. We offer all of our posters at no cost to help support the forensic community.

    REQUEST YOURS
    Product Description

    Lorazepam-13C2-d4 (CRM) (Item No. 18731) is a certified reference material intended for use as an internal standard for the quantification of lorazepam (Item Nos. ISO60202 | 15891) by GC- or LC-MS. Lorazepam is categorized as a benzodiazepine that has anxiolytic properties.1,2 It is a metabolite of diclazepam (Item Nos. 28623 | 15554).3 Formulations containing lorazepam have been used in the treatment of anxiety. Lorazepam-13C2-d4 is regulated as a Schedule IV compound in the United States. Lorazepam-13C2-d4 (CRM) (Item No. 18731) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Miller, L.G., Greenblatt, D.J., Barnhill, J.G., et al. Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased γ-aminobutyric acidA receptor function. J. Pharmacol. Exp. Ther. 246(1), 170-176 (1988).

    2. Baldwin, D., Woods, R., Lawson, R., et al. Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta-analysis. BMJ 342, d1199 (2011).

    3. Moosmann, B., Bisel, P., and Auwärter, V. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal. 6(7-8), 757-763 (2014).